PALO ALTO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BlissBot, a leader in AI-driven neurodevelopmental technology, today announced the official…
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi companyKER-0193, a novel, orally bioavailable…